Your browser doesn't support javascript.
loading
The Dawning of a New Enterprise: RNA Therapeutics for the Skin.
Kieser, Rachel E; Khan, Shaheerah; Bejar, Nada; Kiss, Daniel L.
Afiliação
  • Kieser RE; Center for RNA Therapeutics.
  • Khan S; Department of Cardiovascular Sciences.
  • Bejar N; Houston Methodist Academic Institute, Houston Methodist Research Institute, 6670 Bertner Ave, R10-113, Houston 77030, TX, USA.
  • Kiss DL; Center for RNA Therapeutics.
J Dermatol Skin Sci ; 5(1): 4-13, 2023.
Article em En | MEDLINE | ID: mdl-38435714
ABSTRACT
Despite being under development for decades, RNA therapeutics have only recently emerged as viable drug platforms. The COVID-19 mRNA vaccines have demonstrated the promise and power of the platform technology. In response, novel RNA drugs are entering clinical trials at an accelerating rate. As the skin is the largest and most accessible organ, it has always been a preferred target for drug discovery. This holds true for RNA therapies as well, and multiple candidate RNA-based drugs are currently in development for an array of skin conditions. In this mini review, we catalog the RNA therapies currently in clinical trials for different dermatological diseases. We summarize the main types of RNA-related drugs and use examples of drugs currently in development to illustrate their key mechanism of action.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Dermatol Skin Sci Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Dermatol Skin Sci Ano de publicação: 2023 Tipo de documento: Article